Tempest Therapeutics, Inc. has announced that the U.S. FDA has granted a "Study May Proceed" letter for their Phase 2 clinical trial of TPST-1495, a novel dual receptor inhibitor aimed at treating ...

Many investors view the healthcare sector as a safe haven when the stock market is turbulent. That's understandable. The ...

Lifeward received 510(k) FDA clearance for the ReWalk 7 ... 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical ...

Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial ... "We are focused on the potential FDA approval for CARDAMYST and the opportunity to help the millions of patients suffering from ...

The FDA has approved five novel drugs so far this year. Now, let's take a look at the biotech stocks facing FDA decisions in March 2025. The views and opinions expressed herein are the views and ...

Nearly a third of medical device adverse events were not submitted to the FDA within a 30-day regulatory window, with most ...

Q4 2024 Earnings Call Transcript March 13, 2025 REGENXBIO Inc. beats earnings expectations. Reported EPS is $-1.01, ...

“The FDA’s sBLA acceptance for Gazyva recognizes the need to provide a more effective treatment option for people living with this devastating disease.” “Lupus nephritis is a debilitating ...

Q4 2024 Earnings Call Transcript March 13, 2025 Operator: Hello, and welcome to Nyxoah Fourth Quarter 2024 Earnings ...

Q4 2024 Earnings Call Transcript March 13, 2025 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is ...